To order thisdetailed 795+ page report, please visit this link
Key Inclusions
§ A detailed assessment of the current market landscape ofCAR-T cell therapies based on the type of developer (industry / non-industry),phase of development (preclinical, phase I, phase I/II, phase II, phase III andapproved), therapeutic area (hematological cancer, solid tumor and others),target therapeutic indication (acute lymphoblastic leukemia, non-Hodgkinlymphoma, multiple myeloma, acute myeloid leukemia, brain cancer, chroniclymphocytic leukemia, pancreatic cancer, liver cancer, lung cancer, stomachcancer, ovarian cancer, breast cancer, mesothelioma, colon cancer, Hodgkinlymphoma, sarcoma, bone cancer, melanoma, and others), key target antigen(CD19, BCMA, CD22, CD20, GD2, Meso, CD38, CD123, MUC1, CD30, HER2, GPC3, CD33,EGFR, EGFRvIII, PD-L1, PSMA and others), source of T-cells (autologous /allogeneic), route of administration (intravenous, intratumor, intraperitoneal,intrapleural, intraventricular and others), dose frequency (single dose,multiple dose and split dose), target patient segment (children, adults andseniors), and type of therapy (monotherapy and combination therapy). Further,the chapter provides a list of the most active players (in terms of number ofpipeline candidates) and an insightful logo landscape, highlighting product developersin North America, Europe and the Asia Pacific.
§ Detailed profiles of marketed and mid to late stageclinical products (phase I/II or above); each profile features an overview ofthe therapy, its mechanism of action, dosage information, details on the costand sales information (wherever available), clinical development plan, and keyclinical trial results.
§ An analysis of the CAR constructs of clinical-stage CAR-Ttherapies based on the generation of CAR-T therapy (first generation, secondgeneration, third generation and fourth generation), type of binding domain(murine, humanized, fully human and rabbit derived), type of vector(lentivirus, retrovirus, mRNA and other vectors) and type of co-stimulatorydomain used.
§ An analysis highlighting the key opinion leaders (KOLs) inthis domain. It features a 2×2 representation highlighting the KOLs shortlistedbased on their contributions (in terms of involvement in various clinicalstudies) to this field, and a schematic world map representation, indicatingthe geographical location of eminent scientists / researchers involved in thedevelopment of CAR-T cell therapies.
§ An analysis of the completed, ongoing, and planned clinicalstudies of various CAR-T cell therapies, based on trial registration year andgeographical location of the clinical trial centers. In addition, we haveprovided a list of factors that have influenced the growth of CAR-T therapies,especially in China.
§ An overview of the focus areas of therapy developers (interms of target disease indication), including an assessment of the opportunity(in terms of revenue generation potential from therapy sales) acrossoncological and non-oncological disease indications.
§ A detailed discussion on innovative technology platformsthat are being used for the development of CAR-T cell therapies, along withprofiles of key technology providers, and a competitiveness analysis ofdifferent gene editing platforms (used for the development of CAR-T celltherapies), based on various parameters, such as ease of system design, cost oftechnology, level of toxicity and efficiency of technology.
§ An analysis of the partnerships that have been establishedin the recent past, covering R&D agreements, license agreements (specificto technology platforms and product candidates), product development andcommercialization agreements, manufacturing agreements, clinical trialcollaborations, product supply management agreements, joint ventures andothers.
§ An analysis of the investments that have been made intocompanies that have proprietary CAR-T cell based products / technologies,including seed financing, venture capital financing, capital raised from IPOsand subsequent offerings, grants and debt financing.
§ A case study on manufacturing cell therapy products, highlightingthe key challenges, and a detailed list of contract service providers andin-house manufacturers involved in this space.
§ An elaborate discussion on various factors that form thebasis for the pricing of cell-based therapies. It features different models /approaches that a pharmaceutical company may choose to adopt to decide theprice of a CAR-T cell based therapies that is likely to be marketed in thecoming years.
§ An analysis of the prevalent and emerging trends in thisdomain, as represented on the social media platform, Twitter, highlighting theyearly trend of tweets, most frequently talked about product candidates,popular disease indications, target antigens, and prolific authors and socialmedia influencers.
§ A review of the key promotional strategies that have beenadopted by the developers of the marketed T-cell therapies, namely KYMRIAH® andYESCARTA®.
The report also features thelikely distribution of the current and forecasted opportunity across importantmarket segments, mentioned below:
§ Disease indication
§ Non-Hodgkin lymphoma
§ Multiple myeloma
§ Chronic lymphocyticleukemia
§ Acute lymphoblasticleukemia
§ Follicular lymphoma
§ Mantle cell lymphoma
§ Hepatocellularcarcinoma
§ Colorectal cancer
§ Target antigens
§ CD19
§ BCMA
§ CD19, CD22
§ GPC3
§ EGFR
§ KeyGeographical Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and North Africa
- Rest of the World
The report features inputs from eminentindustry stakeholders, according to whom T-cell immunotherapies are expected tobe the next big step in cancer immunotherapy. The report includes detailedtranscripts of discussions held with the following experts:
§ Tim Oldham (ChiefExecutive Officer, Cell Therapies)
§ Troels Jordansen(Chief Executive Officer, Glycostem Therapeutics)
§ Wei (William) Cao(Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)
§ Miguel Forte (ChiefOperating Officer, TxCell)
§ Adrian Bot (VicePresident, Scientific Affairs, Kite Pharma)
§ Vincent Brichard(Vice President, Immuno-Oncology, Celyad)
§ Brian Dattilo(Manager of Business Development, Waisman Biomanufacturing)
§ Aino Kalervo(Competitive Intelligence Manager, Strategy & Business Development,Theravectys)
§ Xian-Bao Zhan(Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
§ Enkhtsetseg Purev(Assistant Professor of Medicine, University of Colorado)
To request sample pages, please visit this link
Key Questions Answered
§ What are the prevalent R&D trends in CAR-T celltherapies domain?
§ What are the key therapeutic areas for which CAR-T cell therapiesare being / have been developed?
§ What are the various challenges being faced by stakeholdersengaged in this domain?
§ Who are the leading industry and non-industry players inthis market?
§ Which are the key geographies where extensive research on CAR-Tcell therapies is being conducted?
§ Who are the key investors in this domain?
§ Who are the key opinion leaders / experts that can help indriving the development efforts?
§ What kind of partnership models are commonly adopted byindustry stakeholders?
§ What kind of contract manufacturing support is availablefor CAR-T cell therapies, across different regions?
§ What kind of promotional strategies are likely to beadopted for CAR-T cell therapies that are approved and commercialized infuture?
§ What are the factors that are likely to influence theevolution of this upcoming market?
§ How is the current and future market opportunity likely tobe distributed across key market segments?
You may also be interested in the followingtitles:
1. Global T-Cell (CAR-T,TCR, and TIL) Therapy Market (5th Edition), 2021 – 2030
2. mRNA Therapeutics andVaccines Market, 2020-2030
3. Gene Therapy Market(4th Edition): Industry Trends and Global Forecasts, 2020-2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
Facebook Conversations